The Wisconsin Alzheimer's Disease Research Center (ADRC) will build upon the remarkable strengths of the University of Wisconsin (UW) in neuroscience research to provide state-of-the-art resources, infrastructure, and expertise in Alzheimer's disease (AD) and related illnesses. With the major focus on preclinical and early diagnosis and progression of AD, the Wisconsin ADRC will expand the scientific objectives of the Wisconsin Registry for Alzheimer's Prevention (WRAP) and significantly enhance care of Wisconsin residents suffering from the devastations of AD. Comprised of six Cores (i.e., Administrative, Clinical, Data Management and Biostatistics, Neuropathology and Biomarkers, Education and Transfer and the Minority Recruitment Satellite Program), the ADRC builds upon the highly successful UW research program in AD and several recent convergent developments. These developments include a new focus of the UW leadership on AD, substantial institutional and state financial commitment to AD research, presence of several renowned programs in neuroscience on the UW campus, outstanding UW clinical programs, an extensive statewide network of dementia diagnostic clinics, access to minority, low-income and rural populations through the Minority Recruitment Satellite Program (MRSP), acknowledged status of several UW investigators in AD research, and close collaborations between numerous UW centers and institutes in aging and neuroscience research. Among others, these centers and institutes include the Wisconsin Alzheimer's Institute, the UW Waisman Center, the UW Waisman Laboratory for Brain Imaging and Behavior, the NIH/CTSA-funded Institute for Clinical and Translational Research (ICTR), the Institute on Aging, the Madison Veterans Affairs (VA) Geriatric Research, Education and Clinical Center (GRECC), the National Primate Research Center, the Biotechnology Center, the Genome Center, and the Clinical and Translational Research Core (formerly known as the UW GCRC). Given the access to outstanding resources and expertise, the Wisconsin ADRC is well poised to make novel contributions to the field of AD research and provide outstanding clinical care to patients suffering from the devastations of the disease.

Public Health Relevance

The major focus of the Wisconsin ADRC is to identify novel diagnostic tests and potential therapies for the prevention of Alzheimer's disease at a stage when patients have no clinical symptoms (preclinical stage). It is anticipated that such therapies will help reduce the number of individuals suffering from Alzheimer's disease.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG033514-04
Application #
8248238
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J1))
Program Officer
Phelps, Creighton H
Project Start
2009-05-01
Project End
2014-03-31
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
4
Fiscal Year
2012
Total Cost
$1,259,432
Indirect Cost
$410,384
Name
University of Wisconsin Madison
Department
Other Health Professions
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325
Holden, Timothy R; Keller, Sarah; Kim, Alice et al. (2018) Procedural Framework to Facilitate Hospital-Based Informed Consent for Dementia Research. J Am Geriatr Soc 66:2243-2248
Betthauser, Tobey J; Cody, Karly A; Zammit, Matthew D et al. (2018) In vivo characterization and quantification of neurofibrillary tau PET radioligand [18F]MK-6240 in humans from Alzheimer's disease dementia to young controls. J Nucl Med :
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Kamara, Dennis M; Gangishetti, Umesh; Gearing, Marla et al. (2018) Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. J Alzheimers Dis 62:1815-1826
Hao, Ling; Wang, Jingxin; Page, David et al. (2018) Comparative Evaluation of MS-based Metabolomics Software and Its Application to Preclinical Alzheimer's Disease. Sci Rep 8:9291
Bettcher, Brianne M; Johnson, Sterling C; Fitch, Ryan et al. (2018) Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage. J Alzheimers Dis 62:385-397
Mueller, Kimberly D; Koscik, Rebecca L; Clark, Lindsay R et al. (2018) The Latent Structure and Test-Retest Stability of Connected Language Measures in the Wisconsin Registry for Alzheimer's Prevention (WRAP). Arch Clin Neuropsychol 33:993-1005
Zhou, Hao Henry; Singh, Vikas; Johnson, Sterling C et al. (2018) Statistical tests and identifiability conditions for pooling and analyzing multisite datasets. Proc Natl Acad Sci U S A 115:1481-1486
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360

Showing the most recent 10 out of 374 publications